Literature DB >> 25185790

Hepatitis C virus genotype 4 in England: diversity and demographic associations.

Siew-Lin Ngui1, Lisa Brant, Peter V Markov, John-Paul Tung, Oliver G Pybus, Chong-Gee Teo, Mary E Ramsay.   

Abstract

HCV strains belonging to genotype 4 may be gaining endemicity across Continental Europe but the extent of their spread in the United Kingdom is unknown. Sera referred from patients attending hospitals in England between 2004 through 2008 were characterised. A total of 243 sera carried HCV genotype 4. The most common subtypes were 4a (33%) and 4d (35%). Compared to patients infected by 4d, those infected by 4a were 20 times more likely to be Middle Eastern than English, and those infected by non-4a/4d were older, tended to be female, and 50 or 12 times more likely to be Middle Eastern or South Asian, respectively, than English. Persons infected by 4d tended to be English rather than Middle Eastern or South Asian. One group of 4d strains clustered with strains reported from persons in Europe engaged in male homosexual activity. Surveillance of trends in the importation and subsequent spread of HCV genotype 4 and its subtypes is advocated.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  diversity; genotype 4; phylogenetic analysis

Mesh:

Year:  2014        PMID: 25185790     DOI: 10.1002/jmv.24069

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  2 in total

1.  Molecular characterization of HCV in a Swedish county over 8 years (2002-2009) reveals distinct transmission patterns.

Authors:  Josefine Ederth; Camilla Jern; Helené Norder; Lars Magnius; Erik Alm; Björg Kleverman Rognsvåg; Carl-Gustaf Sundin; Mia Brytting; Joakim Esbjörnsson; Mattias Mild
Journal:  Infect Ecol Epidemiol       Date:  2016-02-05

2.  Intravenous drug use - an independent predictor for HCV genotypes 3 and 4 infection among HIV/HCV co-infected patients.

Authors:  Dubravka Salemovic; Ivana Pesic-Pavlovic; Djordje Jevtovic; Ksenija Bojovic; Jovan Ranin; Branko Brmbolic; Maja Stanojevic
Journal:  Arch Med Sci       Date:  2017-04-20       Impact factor: 3.318

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.